Insider · CIK 0001808510
Conor Kilroy
Files at AURA (Aura Biosciences, Inc.). First filing Apr 16, 2025, latest Apr 16, 2026.
In brief
Conor Kilroy files SEC Form 4 as officer at AURA (Aura Biosciences, Inc.). Since Apr 16, 2025, Conor Kilroy has reported 0 open-market buys worth $0 and 3 open-market sells worth $183k, the latest filed on Apr 16, 2026.
A track record needs three past buys with six months of prices behind them; Conor Kilroy has 0, so none is measured yet.
The newest scored trade: sold $82k of AURA on Apr 16, 2026, filed Apr 16, 2026, scored 24 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $143k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AURA: Aura Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | AURAsell Aura Biosciences, Inc. | $82k 11,738 shares | -5% | +44% from low-2% from high | |
| 37Weak | Aura Biosciences, Inc. | $61k 12,079 shares | -7% | +7% from low-31% from high | |
| 29Weak | Aura Biosciences, Inc. | $39k 7,162 shares | -4% | +9% from low-54% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 16, 2026 | AURA Aura Biosciences, Inc. | 11,738 0.02% of outstanding | $82k | Apr 16, 2026 | $61k |
| Feb 17, 2026 | AURA Aura Biosciences, Inc. | 12,079 0.02% of outstanding | $61k | Feb 17, 2026 | none |
| Apr 16, 2025 | AURA Aura Biosciences, Inc. | 7,162 0.01% of outstanding | $39k | Apr 16, 2025 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +14,858 | $0.00 | $0 | 232,693 | Jul 1, 2026 |
| Apr 16, 2026 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -11,738 | $7.02 | $82k | 217,835 | Apr 16, 2026 |
| Mar 2, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +62,339 | $0.00 | $0 | 229,573 | Mar 3, 2026 |
| Mar 2, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +112,661 | $0.00 | $0 | 112,661 | Mar 3, 2026 |
| Feb 17, 2026 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -12,079 | $5.05 | $61k | 167,234 | Feb 17, 2026 |
| Apr 16, 2025 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -7,162 | $5.49 | $39k | 179,313 | Apr 16, 2025 |
| Feb 3, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +90,475 | $0.00 | $0 | 186,475 | Feb 4, 2025 |
| Feb 3, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +59,525 | $0.00 | $0 | 59,525 | Feb 4, 2025 |
| Apr 2, 2024 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +96,000 | $0.00 | $0 | 96,000 | Apr 4, 2024 |
| Apr 2, 2024 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +144,000 | $0.00 | $0 | 144,000 | Apr 4, 2024 |
Questions about Conor Kilroy
Answered from the filings on this page, as of the latest one.
Is Conor Kilroy buying or selling?
In the last 12 months Conor Kilroy reported 0 open-market buys worth $0 and 2 open-market sells worth $143k on SEC Form 4; the latest was sold $82k of AURA on Apr 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Conor Kilroy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Conor Kilroy has 0.
Where does Conor Kilroy file Form 4?
Conor Kilroy has filed Form 4 at AURA (Aura Biosciences, Inc.) as General Counsel and Secretary. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.